Strategy
As ocrelizumab biosimilar entry is coming closer, Biogen hopes that development partner Genentech will protect the franchise with new Ocrevus products.
The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.
Coherus is fully exiting the biosimilars space after striking a final deal worth up to $558m to divest its Udenyca US pegfilgrastim franchise to Accord parent company Intas.
Celltrion Group chairman outlines new plans for the Korean biosimilars giant to move into the CDMO sector and updates on new drug development activities.
Viatris is shedding another of its off-patent interests, striking a deal for Safecor Health to acquire its US unit-dose packaging business.
Zentiva is moving ahead with its takeover of Apontis Pharma after its voluntary public purchase offer resulted in it securing almost 84% of share capital and a more than 85% share of voting rights.
Korean biosimilars giant Samsung Bioepis and leading French generics firm Biogaran have both announced new leaders, while Xbrane Biopharma is looking for a fresh finance chief.
At the recent Jefferies Global Healthcare Conference in London, Sandoz’s CEO Richard Saynor colorfully shared the firm’s dreams and achievements, and the market’s current state of play.
Zentiva has responded to recent rumors that owner Advent International may be looking to sell the firm in a deal worth as much as €5bn.
Lanreotide supply challenges could impact Cipla’s US revenues in the coming quarter, while the firm hopes it can seize emerging opportunities in the GLP-I segment in India, where Novo Nordisk and Eli Lilly are progressing filings for their blockbuster products.
Sandoz has raised its full-year guidance on the back of third-quarter results that saw the firm enjoy growth of more than a tenth, with biosimilars sales up by a whopping 37%.
Only days after its initial announcement, Hypera Pharma has refused EMS’ proposed merger on grounds of undervaluation and different strategic priorities.
Generics Bulletin previews the most noteworthy and anticipated events for November 2024.
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.
In the wake of its recent acquisition of dermatology assets from Canute Pharma, UK-based Aspire Pharma is looking to new frontiers of expansion in Europe and beyond. Chief executive Richard Condon talks to Generics Bulletin about the next steps on the niche generics and value added medicines firm’s journey.
Celltrion gave updates on several business aspects and reassured its shareholders that the delayed insurance listing for Zymfentra will not affect its set annual sales goal.
Backed by AI and former FDA official Janet Woodcock, Every Cure is set to identify approved drugs for patients who don’t have treatment options around the world.
Zentiva has launched a bid to take control of German “single pill company” Apontis Pharma, with a €10-per-share offer that values the enterprise at €85m. If successful, Zentiva plans to establish the firm as a standalone branded division.
Delegates from European institutions and industry representatives unpacked the many challenges of improved access to critical medicines on the continent in a session at this year’s European Health Forum.
Days after Gilead’s signing of voluntary licensing with six generic manufacturers for its HIV drug Sunleca, ViiV announced its commitment to ramping up Apretude’s supply to countries in need.